JP2019516720A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516720A5
JP2019516720A5 JP2018560597A JP2018560597A JP2019516720A5 JP 2019516720 A5 JP2019516720 A5 JP 2019516720A5 JP 2018560597 A JP2018560597 A JP 2018560597A JP 2018560597 A JP2018560597 A JP 2018560597A JP 2019516720 A5 JP2019516720 A5 JP 2019516720A5
Authority
JP
Japan
Prior art keywords
compound
general formula
group
ethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018560597A
Other languages
English (en)
Japanese (ja)
Other versions
JP7034093B2 (ja
JP2019516720A (ja
Filing date
Publication date
Priority claimed from GBGB1608777.7A external-priority patent/GB201608777D0/en
Application filed filed Critical
Publication of JP2019516720A publication Critical patent/JP2019516720A/ja
Publication of JP2019516720A5 publication Critical patent/JP2019516720A5/ja
Application granted granted Critical
Publication of JP7034093B2 publication Critical patent/JP7034093B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018560597A 2016-05-18 2017-05-18 胆汁酸誘導体、特に、オベチコール酸の合成のための中間体 Active JP7034093B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1608777.7 2016-05-18
GBGB1608777.7A GB201608777D0 (en) 2016-05-18 2016-05-18 Compounds
PCT/GB2017/051385 WO2017199033A1 (en) 2016-05-18 2017-05-18 Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid

Publications (3)

Publication Number Publication Date
JP2019516720A JP2019516720A (ja) 2019-06-20
JP2019516720A5 true JP2019516720A5 (https=) 2020-07-02
JP7034093B2 JP7034093B2 (ja) 2022-03-11

Family

ID=56320629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560597A Active JP7034093B2 (ja) 2016-05-18 2017-05-18 胆汁酸誘導体、特に、オベチコール酸の合成のための中間体

Country Status (14)

Country Link
US (2) US10968250B2 (https=)
EP (2) EP3848382B1 (https=)
JP (1) JP7034093B2 (https=)
KR (1) KR102458265B1 (https=)
CN (1) CN109415407B (https=)
AU (1) AU2017266539B2 (https=)
EA (1) EA037584B1 (https=)
ES (2) ES2970336T3 (https=)
GB (1) GB201608777D0 (https=)
HR (1) HRP20211128T1 (https=)
HU (1) HUE054851T2 (https=)
MX (1) MX378591B (https=)
PT (1) PT3458469T (https=)
WO (1) WO2017199033A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608776D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
EP3431486A1 (en) * 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN111138509B (zh) * 2018-11-02 2022-12-06 东莞东阳光药物研发有限公司 奥贝胆酸的制备方法
CN111072744B (zh) * 2019-12-03 2021-09-14 江苏佳尔科药业集团股份有限公司 一种以ba为原料合成熊去氧胆酸的方法
CN114315945A (zh) * 2020-09-28 2022-04-12 四川澄华生物科技有限公司 一种胆甾酸及其衍生物的除杂方法
CN112341516B (zh) * 2020-11-14 2022-07-15 湖南科瑞生物制药股份有限公司 5,6-环氧类固醇类化合物及其制备方法和应用
CA3235506A1 (en) * 2021-11-02 2023-05-11 Sandhill One, Llc High purity non-animal derived udca

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624748A (en) 1950-09-09 1953-01-06 Upjohn Co Bisnorchola-4, 6-dien-3-one-22-al
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
WO1993021259A1 (en) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Dendritic based macromolecules and method of production
AU6392894A (en) 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Chemical synthesis of squalamine
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
AU2002308295B2 (en) 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
US20090062256A1 (en) 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007210888A (ja) * 2006-01-12 2007-08-23 Mitsubishi Chemicals Corp ステロイド化合物の製造方法
CN101374854A (zh) * 2006-01-12 2009-02-25 三菱化学株式会社 甾类化合物的制备方法
JP2010517931A (ja) 2006-02-14 2010-05-27 インターセプト ファーマシューティカルズ, インコーポレイテッド Fxr媒介性の疾患または状態の予防または治療用のfxrリガンドとしての胆汁酸誘導体
PT2040713E (pt) 2006-06-27 2014-10-13 Intercept Pharmaceuticals Inc Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr
AU2008209566C1 (en) 2007-01-19 2013-02-14 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
EA020310B1 (ru) 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
CN102282157B (zh) 2008-11-19 2017-02-22 英特塞普特医药品公司 G蛋白偶联受体5(tgr5)调节剂及其使用方法
ES2663948T3 (es) 2008-11-19 2018-04-17 Intercept Pharmaceuticals, Inc. Moduladores de TGR5 y método de uso de los mismos
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
NZ734451A (en) 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
AU2013334122B2 (en) 2012-10-26 2017-11-02 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
SG11201503697TA (en) 2012-11-28 2015-06-29 Intercept Pharmaceuticals Inc Treatment of pulmonary disease
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
CA2912139C (en) 2013-05-14 2021-04-20 Roberto Pellicciari 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
JP2016521683A (ja) 2013-05-24 2016-07-25 ネステク ソシエテ アノニム 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
US10407462B2 (en) 2014-05-29 2019-09-10 Bar Pharmaceuticals S.R.L. Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
WO2016073767A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
TWI688571B (zh) * 2014-11-19 2020-03-21 英商Nzp英國有限公司 化合物(四)
US10538550B2 (en) * 2014-11-19 2020-01-21 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal FXR modulators
KR102526631B1 (ko) * 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 스테로이드 fxr 조절인자를 제조하기 위한 중간체로서의 6-알킬-7-하이드록시-4-엔-3-온 스테로이드
US10131688B2 (en) * 2014-11-19 2018-11-20 NZP UK Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal FXR modulators
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
JP2017535570A (ja) 2014-11-26 2017-11-30 エナンタ ファーマシューティカルズ インコーポレイテッド Fxr/tgr5アゴニストとしての胆汁酸類似体およびその使用方法
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN106279328A (zh) 2015-05-20 2017-01-04 重庆药友制药有限责任公司 一种制备6α-烷基鹅去氧胆酸的方法
EP3310801B1 (en) 2015-06-19 2021-04-07 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
CN106397522A (zh) 2015-07-31 2017-02-15 中国人民解放军军事医学科学院毒物药物研究所 3,7‑二(叔丁基二甲基硅基氧基)‑6‑烯‑5β‑胆烷‑24‑酸甲酯
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106478756A (zh) 2015-09-02 2017-03-08 中美华世通生物医药科技(武汉)有限公司 Oca-e单晶及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用
GB201608779D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds

Similar Documents

Publication Publication Date Title
JP2019516720A5 (https=)
EP2084174B1 (en) Preparation of nucleosides ribofuranosyl pyrimidines
RU2017114156A (ru) N-ацетилгалактозаминовые (galnac) фосфорамитиды, их конъюгаты с нуклеиновыми кислотами и их применение
JP2012503621A5 (https=)
JP2007530450A5 (https=)
JPH11315072A5 (https=)
CA2454306A1 (en) Substituted dihydro 3-halo-1h-pyrazole-5-carboxylates their preparation and use
RU2018143237A (ru) Катионный липид
JP2019516717A5 (https=)
JP2010132690A (ja) 2−(6−置換−1,3−ジオキサン−4−イル)酢酸誘導体の製造方法
JP2017534669A5 (https=)
JP2010532365A5 (https=)
JP2019516729A5 (https=)
JP2018502174A5 (https=)
JP2012532894A5 (https=)
KR960703887A (ko) 쿠마린 및 카르보스티릴을 pla₂- 억제제로서 사용하는 방법, 및 쿠마린 및 카르보스티릴, 및 이것들의 제조 방법 및 이것들을 함유하는 약제(use of coumarins and carbostyrils as pla₂-inhibitors. new coumarins and car-bostyrils. process for preparing the same and medica-ments)
RU2223958C2 (ru) Новый способ получения ингибитора протеазы
GB1460713A (en) 7-fluoro substituted phenothiazines method for preparation thereof and compositions bladed rotor for a gas turbine engine
SI2576565T1 (en) Synthesis of carbanucleoside and its new useful intermediates
ATE475653T1 (de) Verfahren zur herstellung von valsartan
RU97112894A (ru) Производные 10-деацетил-14бета-гидроксибаккатина iii, способ их получения и композиции, содержащие эти соединения
RU2003114754A (ru) Способ получения бисбензазолиловых соединений
KR840004726A (ko) 5-하이드록시트립타민 길항제인 퀴놀린 유도체의 제조방법 및 그 제약조성물
JP6423936B2 (ja) 放射ヨウ素標識された3−フルオロプロピル−NOR−β−CITの調製
KR870007167A (ko) 페닐 나프티리딘의 제조방법